SpringerProtocols: Abstract: Tailoring Kinetics of Antibodies Using Focused Combinatorial Libraries

Tailoring Kinetics of Antibodies Using Focused Combinatorial Libraries

By: Herren Wu³, Ling-Ling An³

Abstract

Full Text

Download PDF (193K)

Antibodies have been used extensively for diagnostic applications for decades. Antibodies also can be used to target specific cells or specific molecules to produce agonist, antagonist, or neutralizing activity. Antibody therapies have been applied successfully in the treatment of several human diseases (1). The advantages of antibodies over other molecules are that they have high affinity for their targets and they bind to targets with high specificity. Antibodies, with six highly diversified complementaritydetermining regions (CDRs) supported by stable β-sheet framework regions, are capable of binding virtually any molecule including proteins, carbohydrates, nucleic acids, and haptens. The intrinsic features of specificity and affinity when combined offer a great advantage in the discovery of a wide-range of lead drug candidates.

Affiliation(s): (3) MedImmune Inc., Gaithersburg, MD

Book Title: Recombinant Antibodies for Cancer Therapy: Methods and Protocols

Series: Methods in Molecular Biology | Volume: 207 | Pub. Date: Sep-16-2002 | Page Range: 213-233 | DOI: 10.1385/1-59259-334-8:213

Subject: Cancer Research

References

Download References

1.	Glennie M. J. and Johnson P. W. M. (2000). Clinical trials of antibody therapy. Immunol. Today 21, 403–410. <Occurrence Type="DOI"><Handle>10.1016/S0167-5699(00)01669-8</Handle></Occurrence>

2.	Smith G. P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317.

3.	McCafferty J., Griffiths A. D., Winter G., and Chiswell D. J. (1990). Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554.

4.	Barbas C. F., Kang A. S., Lerner R. A., and Benkovic S. J. (1991). Assembly of combinatorial libraries on phage surfaces: The gene III site. Proc. Natl. Acad. Sci. USA 88, 7978–7982.

5.	Chang C. N., Landolfi N. F., and Queen C. (1991). Expression of antibody Fab domains on bacteriophage surfaces. Potential use for antibody selection. J. Immunol. 147, 3610–3614.

6.	Hoogenboom H. R., Griffiths A. D., Johnson K. S., Chiswell D. J., Hudson P., and Winter G. (1991). Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 19, 4133–4137.

7.	Burton D. R., Barbas C. F., Persson M. A. A., Koenig S., Chanock R. M., and Lerner R. A. (1991). A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10,134–10,137.

8.	Zebedee S. L., Barbas C. F., Hom Y.-L., Caothien R. H., Graff R., DeGraw J., et al. (1992). Human combinatorial antibody libraries to hepatitis B surface antigen. Proc. Natl. Acad. Sci. USA 89, 3175–3179.

9.	Marks J. D., Hoogenboom H. R., Bonnert T. P., McCafferty J., Griffiths A. D., and Winter G. (1991). By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581–597. <Occurrence Type="DOI"><Handle>10.1016/0022-2836(91)90498-U</Handle></Occurrence>

10.	Griffiths A. D., Malmqvist M., Marks J. D., Bye J. M., Embleton M. J., McCafferty J., et al. (1993). Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 12, 725–734.

11.	Barbas C. F., Bain J. D., Hoesktra D. M., and Lerner R. A. (1992). Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc. Natl. Acad. Sci. USA 89, 4457–4461.

12.	Hoogenboom H. R. and Winter G. (1992). By-passing immunisation. Human antibodies from synthetic repertoires of germline V_H gene segments rearranged in vitro. J. Mol. Biol. 227, 381–388. <Occurrence Type="DOI"><Handle>10.1016/0022-2836(92)90894-P</Handle></Occurrence>

13.	Foote J. and Milstein C. (1991). Kinetic maturation of an immune response. Nature 352, 530–523.

14.	Perelson A. S. and Oster G. F. (1979). Theoretical studies of clonal selection: minimal antibody repertoire size and reliability of self-non-self discrimination. J. Theor. Biol. 81, 645–670. <Occurrence Type="DOI"><Handle>10.1016/0022-5193(79)90275-3</Handle></Occurrence>

15.	Vaughan T. J., Williams A. J., Pritchard K., Osbourn J. K., Pope A. R., Earnshaw J. C., et al. (1996). Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14, 309–314.

16.	Sheets M. D., Amersdorfer P., Finnern R., Sargent P., Lindovist E., Schier R., et al. (1998). Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc. Natl. Acad. Sci. USA 95, 6157–6162.

17.	de Haard H. J., van Neer N., Reurs A., Hufton S. E., Roovers R. C., Henderikx P., et al. (1999). A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274, 18,218–18,230.

18.	Sblattero D. and Bradbury A. (2000). Exploiting recombination in single bacteria to make large phage antibody libraries. Nat. Biotechnol. 18, 75–80.

19.	Griffiths A. D., Williams S. C., Hartley O., Tomlinson I. M., Waterhouse P., Crosby W. L., et al. (1994). Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13, 3245–3260.

20.	Knappik A., Ge L., Honegger A., Pack P., Fischer M., Wellnhofer G., et al. (2000). Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296, 57–86.

21.	de Bruin R., Spelt K., Mol J., Koes R., and Quattrocchio F. (1999). Selection of highaffinity phage antibodies from phage display libraries. Nature Biotechnol. 17, 397–399.

22.	Usinger W. R. and Lucas A. H. (1999). Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 67, 2366–2370.

23.	Johnson S., Griego S. D., Pfarr D. S., Doyle M. L., Woods R., Carlin D., et al. (1999). A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J. Infect. Dis. 180, 35–40.

24.	Mita H., Yasueda H., and Akiyama K. (2000). Affinity of IgE antibody to antigen influences allergen-induced histamine release. Clin. Exp. Allergy 30, 1583–1589.

25.	Parren P. W. H. I., Mondor I., Naniche D., Ditzel H. J., Klasse P. J., Burton D. R., and Sattentau Q. J. (1998). Neutralization of human immunodeficiency virus type 1 by anti body to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 72, 3512–3519.

26.	Gram H., Marconi L. A., Barbas C. F., Collet T. A., Lerner R. A., and Kang A. S. (1992). In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc. Natl. Acad. Sci. USA 89, 3576–3580.

27.	Yelton D. E., Rosok M. J., Cruz G., Cosand W. L., Bajorath J., et al. (1995). Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. J. Immunol. 155, 1994–2004.

28.	Yang W. P., Green K., Pinz-Sweeney S., Briones A. T., Burton D. R., and Barbas C. F. (1995). CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol. 254, 392–403.

29.	Schier R., Bye J., Apell G., McCall A., Adams G. P., Malmqvist M., et al. (1996). Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinitydriven selection. J. Mol. Biol. 255, 28–43.

30.	Schier R., McCall A., Adams G. P., Marshall K. W., Merritt H., Yim M., et al. (1996). Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263, 551–567.

31.	Thompson J., Pope T., Tung J. S., Chan C., Hollis G., Mark G., and Johnson K. S. (1996). Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. J. Mol. Biol. 256, 77–88.

32.	Schier R., Balint R. F., McCall A., Apell G., Larrick J. W., and Marks J. D. (1996). Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Gene 169, 147–155. <Occurrence Type="DOI"><Handle>10.1016/0378-1119(95)00821-7</Handle></Occurrence>

33.	Wu H., Beuerlein G., Nie Y., Smith H., Lee B. A., Hensler M., et al. (1998). Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized MAb. Proc. Natl. Acad. Sci. USA 95, 6037–6042.

34.	Chowdhury P. S. and Pastan I. (1999). Improving antibody affinity by mimicking somatic hypermutation in vitro. Nature Biotechnol. 17, 568–572.

35.	Boder E. T., Midelfort K. S., and Wittrup K. D. (2000). Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. USA 97, 10,701–10,705.

36.	Adams G. P., Schier R., Marshall K., Wolf E. J., McCall A. M., Marks J. D., and Weiner L. M. (1998). Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58, 485–490.

37.	Viti F., Tarli L., Giovannoni L., Zardi L., and Neri D. (1999). Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59, 347–352.

38.	Adams G. P. and Schier R. (1999). Generating improved single-chain Fv molecules for tumor targeting. J. Immunol. Methods 231, 249–260. <Occurrence Type="DOI"><Handle>10.1016/S0022-1759(99)00161-1</Handle></Occurrence>

39.	Glaser S. M., Yelton D. E., and Huse W. D. (1992). Antibody engineering by codonbased mutagenesis in a filamentous phage vector system. J. Immunol. 149, 3903–3913.

40.	Martin F., Toniatti C., Salvati A. L., Ciliberto G., Cortese R., and Sollazzo M. (1996). Coupling protein design and in vitro selection strategies: improving specificity and affinity of a designed beta-protein IL-6 antagonist. J. Mol. Biol. 255, 86–97.

41.	Hemminki A., Niemi S., Hoffren A. M., Hakalahti L., Soderlund H., and Takkinen K. (1998). Specificity improvement of a recombinant anti-testosterone Fab fragment by CDRIII mutagenesis and phage display selection. Protein Eng. 11, 311–319.

42.	Chames P. and Baty D. (1998). Engineering of an anti-steroid antibody: amino acid substitutions change antibody fine specificity from cortisol to estradiol. Clin. Chem. Lab Med. 36, 355–359.

43.	Willuda J., Honegger A., Waibel R., Schubiger P. A., Stahel R., Zangemeister-Wittke U., and Pluckthun A. (1999). High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res. 59, 5758–5767.

44.	Griffiths G. M., Berek C., Kaartinen M., and Milstein C. (1984). Somatic mutation and the maturation of immune response to 2-phenyl oxazolone. Nature 312, 271–275.

45.	Sandberg W. S. and Terwilliger T. C. (1993). Engineering multiple properties of a protein by combinatorial mutagenesis. Proc. Natl. Acad. Sci. USA 90, 8367–8371.

46.	Moore J. C. and Arnold F. H. (1996). Directed evolution of a para-nitrobenzyl esterase for aqueous-organic solvents. Nature Biotechnol. 14, 458–467.

47.	Wells J. A., Cunningham B. C., Graycar T. P., and Estell D. A. (1987). Recruitment of substrate-specificity properties from one enzyme into a related one by protein engineering. Proc. Natl. Acad. Sci. USA 84, 5167–5171.

48.	Wells J. A., Powers D. B., Bott R. R., Graycar T. P., and Estell D. A. (1987). Designing substrate specificity by protein engineering of electrostatic interactions. Proc. Natl. Acad. Sci. USA 84, 1219–1223.

49.	Russell A. J. and Fersht A. R. (1987). Rational modification of enzyme catalysis by engineering surface charge. Nature 328, 496–500.

50.	Huse W. D., Stinchcombe T. J., Glaser S. M., Starr L., Maclean M., et al. (1992). Application of a filamentous phage pVIII fusion protein system suitable for efficient production, screening, and mutagenesis of F(ab) antibody fragments. J. Immunol. 149, 3914–3920.

51.	Glaser S., Kristensson K., Chilton T., and Huse W. D. (1995). Engineering the antibody combining site by codon-based mutagenesis in a filamentous phage display system, in Antibody Engineering, 2^nd ed. (Borrebaeck C. A. K., ed.), Oxford University Press, Oxford, pp. 117–131.

52.	Kunkel T. A. (1985). Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl. Acad. Sci. USA 82, 488–492.

53.	Perlak F. J. (1990). Single step large scale site-directed in vitro mutagenesis using multiple oligonucleotides. Nucleic Acids Res. 18, 7457–7458.

54.	Wu H., Nie Y., Huse W. D., and Watkins J. D. (1999). Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J. Mol. Biol. 294, 151–162.

55.	Wells J. A. (1990). Additivity of mutational effects in proteins. Biochemsitry 29, 8509–8517.

56.	Watkins J. D., Beuerlein G., Wu H., McFadden P. R., Pancook J. D., and Huse W. D. (1998). Discovery of human antibodies to cell surface antigens by capture lift screening of phage-expressed antibody libraries. Anal. Biochem. 256, 169–177.

57.	Watkins J. D., Beuerlein G., Pecht G., McFadden P. R., Glaser S. M., and Huse W. D. (1997). Determination of the relative affinities of antibody fragments expressed in Escherichia coli by enzyme-linked immunosorbent assay. Anal. Biochem. 253, 37–45.

Comments (Loading...)

Post comment/View all comments